Based: Paris
Founded: 1999

Why It's Fierce: Ever since a group of scientists from the Institut Pasteur launched Diatos five years ago, the global company (there's an affiliated lab in Belgium and an office in Palo Alto, California) has drawn a lot of favorable attention. Most recently, it won the first-ever biotech award from the City of Paris. Diatos' specialty is licensing-in compounds while developing its own anti-cancer agents. It licensed its lead compound –- DTS-201 -– from Medarex last year. And it's using two peptide-based technologies to push the experimental drugs in its own pipeline while renting it out to other companies as well. Diatos can now count six biotech collaborators for its DPV technology, which is aimed at reducing toxicity and improving efficacy -- both keys to a successful cancer drug. The venture capital crowd has picked up the scent, sinking €33 million into the venture since 1999.

What to look for: DTS-201 starts Phase I/II clinical trials later this year.


Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.